13 companies overcome key patents for Entresto

Entresto dispute effectively wins first trial

Hanmi succeeded in targeting 4 registered patents

Domestic pharmaceutical companies won the first trial of the patent dispute over Novartis' Entresto (Valsartan + Sacubitril).

 

it is predicted that domestic pharmaceutical companies will soon launch generics for Entresto as they succeeded in targeting use patents that were considered key patents among Entresto patents.

 

◆ 13 domestic pharmaceutical companies succeeded in overcoming use patents that are key to Entresto According to the pharmaceutical industry on the 27th, the Korean Intellectual Property Tribunal recently ruled on the invalidation of Entresto filed by 13 pharmaceutical companies, including Hanmi Pharmaceutical, against Novartis.

 

It is significant in that Korean companies succeeded in targeting usage patents, which were classified as key patents among Entresto's five patents (including one unregistered).

 

Entresto is protected by a total of five layers of patents.

 

▲ a pharmaceutical patent that expires in November 2028, ▲ a pharmaceutical patent that expires in January 2029, ▲Salt and hydrate patents that expire in November 2026 (not registered), ▲Patents for use that expire in July 2027 and ▲Decisive patent expiring in September 2027.

 

Entresto is a combination of Valsartan and Sacubitril, and there is no separate substance patent.

 

Instead, the use patent actually serves as a material patent.

 

◆ Hanmi Pharmaceutical leads Entresto patent targeting Among many domestic pharmaceutical companies, Hanmi Pharmaceutical is the fastest target of Entresto patents.

 

Except for one unregistered product, it overcame all four patents.

 

In the case of pharmaceutical patents that expire in 2028, only Hanmi Pharmaceutical has been avoided.

 

In the case of another pharmaceutical patent that expires in 2029, Hanmi Pharmaceutical and Daewoong Pharmaceutical succeeded in targeting it.

 

In addition, Crystalline patents for Entresto were overcome by Hanmi Pharmaceutical, Elyson, Yoo Young, Hana, Hanlim, Ann-gook, Chong Kun Dang, Daewoong Pharmaceutical, Genuonescience, Samjin, Genupharma, CTC bio, and Yuyu.

 

Hanmi Pharmaceutical succeeded in targeting all four patents registered with Entresto for the first time in Korean history, crossing all hurdles for the release of generics.

 

Hanmi Pharmaceutical, which meets the requirements for generic for exclusivity, plans to release generic as soon as it obtains the license.